PMID- 12903801
OWN - NLM
STAT- MEDLINE
DCOM- 20030926
LR  - 20071115
IS  - 1476-0584 (Print)
IS  - 1476-0584 (Linking)
VI  - 2
IP  - 3
DP  - 2003 Jun
TI  - Melacine: an allogeneic melanoma tumor cell lysate vaccine.
PG  - 353-68
AB  - Cancer vaccines have represented the holy grail of tumor immunology to many. In 
      2003, there are innumerable approaches to active specific immunotherapy for 
      cancer. The identification of tumor antigens recognized by and able to activate 
      human T-lymphocytes has heightened the enthusiasm for this approach. Melanoma is 
      one of the diseases that has been primarily targeted by vaccine approaches. The 
      identification of peptides and proteins associated with cancer has provided 
      strategies to target specific components of the cancer cell. However, older 
      vaccines utilizing products from whole cells may have a number of advantages. 
      Melacine (Corixa Corp.) is an allogeneic melanoma tumor cell lysate combined with 
      the adjuvant DETOX. Pioneered by Malcolm Mitchell, it has rare but confirmed 
      antitumor activity in metastatic melanoma (5-10%). However, previous analysis of 
      responses in advanced disease and a recent analysis in early-stage adjuvant 
      trials suggest that Melacine may have its greatest benefit in a large subset of 
      melanoma patients who express either the human leukocyte antigen (HLA) class I 
      antigens A2 and/or HLA-C3. This finding must now be confirmed in a large 
      perspective observation-controlled clinical trial to solidify the role of 
      Melacine as an effective cancer vaccine in melanoma.
FAU - Sosman, Jeffrey A
AU  - Sosman JA
AD  - Melanoma Program, Vanderbilt Ingram Cancer Center, Division of 
      Hematology/Oncology, Nashville, TN 37027, USA. jeff.sosman@vanderbilt.edu
FAU - Sondak, Vernon K
AU  - Sondak VK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Vaccines
JT  - Expert review of vaccines
JID - 101155475
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytoskeletal Proteins)
RN  - 0 (Drug Combinations)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunologic Factors)
RN  - 0 (Interferon-alpha)
RN  - 0 (Isoantigens)
RN  - 0 (Lipid A)
RN  - 0 (Melacine)
RN  - 0 (Vaccines, Subunit)
RN  - 0 (detox adjuvant)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Antigens, Neoplasm/immunology
MH  - Cancer Vaccines/immunology/standards/*therapeutic use
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Combined Modality Therapy
MH  - Cytoskeletal Proteins/immunology
MH  - Drug Combinations
MH  - HLA Antigens/immunology
MH  - Humans
MH  - Immunologic Factors/therapeutic use
MH  - *Immunotherapy, Active
MH  - Interferon-alpha/therapeutic use
MH  - Isoantigens/immunology
MH  - Lipid A/*analogs & derivatives/immunology
MH  - Melanoma/epidemiology/immunology/*therapy
MH  - Quality Control
MH  - Randomized Controlled Trials as Topic
MH  - T-Lymphocyte Subsets/immunology
MH  - Treatment Outcome
MH  - Vaccines, Subunit/immunology/therapeutic use
RF  - 107
EDAT- 2003/08/09 05:00
MHDA- 2003/09/27 05:00
CRDT- 2003/08/09 05:00
PHST- 2003/08/09 05:00 [pubmed]
PHST- 2003/09/27 05:00 [medline]
PHST- 2003/08/09 05:00 [entrez]
AID - ERV020303 [pii]
AID - 10.1586/14760584.2.3.353 [doi]
PST - ppublish
SO  - Expert Rev Vaccines. 2003 Jun;2(3):353-68. doi: 10.1586/14760584.2.3.353.